| Document |
Document Title |
|
WO/2007/118717A2 |
The present invention relates to a method for the reliable and reproducible preparation of 4-[17β-methoxy-17α-methoxymethyl-3-oxoestra-4,9-dien-llβ-
yl]benzaldehyde (E)-oxime (asoprisnil) on the pilot and manufacturing scale. Asopris...
|
|
WO/2007/092574A2 |
The invention encompasses a crystalline form of ciclesonide characterized by an XRD pattern having peaks at about 1 1.0, 14.8, 15.7, 16.5, and 22.8 degrees two-theta ± 0.2 degrees two-theta, methods of its preparation and pharmaceutical...
|
|
WO/2007/063930A1 |
Disclosed is a novel method for producing [{(5Z,7E)-(1S,3R,20S)-1,3-dihydroxy-9,10-secopregna-5,7,10(1
9),16-tetraen-20-yl}oxy]-N-(2,2,3,3,3-pentafluoropropyl) acetamide which is characterized by ring-opening a compound represented by th...
|
|
WO/2007/056181A2 |
Provided is a process for increasing the 22R/22S epimeric ratio of ciclesonide.
|
|
WO/2007/025780A2 |
Compounds of the formula (I), (R1 is one of a wide range of substituents; R2 = H, halogen and R3 = H, hydroxymethyl or CR2R3 = cyclopropyl ring; CR4R5 is one of formula (II), formula (III) and formula (IV) Ra and Rb are a bond between ca...
|
|
WO/2007/003286A2 |
The invention relates to plant extracts, especially based on species of the genus Agapanthus and combinations thereof with other extracts deriving from other plants. The invention further relates to the isolation, purification and identi...
|
|
WO/2006/137069A2 |
The invention relates to stable preparations of saponin nanovesicles, which can encapsulate active biological or chemical materials such as drugs, pesticides, vitamins, minerals and nutrients, and protect them. The preparations can be us...
|
|
WO/2006/138212A1 |
A mutual prodrug of a corticosteroid and a substituted phenylphosphate (β-agonist derivative) for formulation for delivery by aerosolization to inhibit pulmonary inflammation and bronchoconstriction is described. The mutual prodrug is p...
|
|
WO/2006/125800A1 |
The present invention relates to novel substituted steroid derivatives which represent selectiv inhibitors of the 17β-hydroxysteroid dehydrogenase type I (17β-HSD1) and, in addition, which may represent inhibitors of the steroid sulpha...
|
|
WO/2006/124956A1 |
As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disord...
|
|
WO/2006/113368A1 |
Amooranin (AMR) has been found to cause tumor cell death through G2/M cell cycle arrest, caspase activation, and apoptosis. Furthermore, it has been demonstrated that AMR is a substrate for P-glycoprotein. Based on these activities, AMR ...
|
|
WO/2006/085334A2 |
The invention relates to novel betulinic acid derivatives of formula (I), wherein R is C (=CH2) CH3 or CH(CH3) 2; R2 together with the adjacent carbonyl group forms a carboxylic acid, carboxylic acid ester or amide or substituted amide; ...
|
|
WO/2006/084083A2 |
The present invention is directed to devices for delivering agents to a vaginal tract, a device of the invention comprises a non-porous polymeric material substantially impermeable to an environment of the vaginal tract, the non-porous p...
|
|
WO/2006/082126A1 |
The invention concerns a triterpene alkaloid of general formula (I). The invention also concerns a method for making same and use thereof as medicine.
|
|
WO2004085458A9 |
A steroid comprising a 17-spirolactone or corresponding open lactone structure is obtained by carbonylation of a 17-alkenyl or 17-alkynyl substrate. A 17-alkenyl intermediate may be prepared by semi-hydrogenation of a 17-alkynyl group. M...
|
|
WO/2006/048665A2 |
The invention provides sarsasapogenin in novel amorphous, crystalline, solvated and hydrated forms, and the use thereof in manufacturing pharmaceutical or edible grade sarsasapogenin and its derivatives.
|
|
WO/2006/041121A1 |
It is intended to provide: a remedy and/or a preventive for a chronic skin disease which comprises, as the active ingredients, (a) a phosphodiesterase (PDE)-IV inhibitor or a pharmacologically acceptable salt thereof and (b) a steroid dr...
|
|
WO/2006/018019A2 |
The invention relates to an inhibitor of 11ß hydroxysteroid dehydrogenase (11ß-HSD), which exclusively inhibits 11ß hydroxysteroid dehydrogenase type 1, but not 11ß hydroxysteroid dehydrogenase type 2.
|
|
WO/2005/113577A1 |
The present invention relates to a method for the preparation of trilostane from (4&agr ,5&agr ,17β)-4,5-epoxyandrost-2-eno(2,3-d)isoxazol-17-o1 as a precursor compound, the method comprising the steps of a) dissolving the precursor com...
|
|
WO/2005/110958A1 |
Disclosed is a method for oxidizing an alcohol in an amide solvent using a mixed reagent containing hydrogen peroxide and a tungsten catalyst.
|
|
WO/2005/105824A1 |
A precess for preparation of timosaponin B II, which uses Chinese traditional drug Anemarrhena Rhizome or newly collected rhizoma or fibrous root of Anemarrhena Asphodeloides Bge. as raw material, and comprises isolation of tiBosaponin B...
|
|
WO/2005/105825A2 |
The invention provides smilagenin in novel amorphous, crystalline, hydrated and solvated forms, and the use thereof in manufacturing pharmaceutical or edible grade smilagenin and its derivatives.
|
|
WO/2005/100377A1 |
Azacyclosteroid histamine-3 receptor ligands, pharmaceutical compositions comprising such compounds, and methods for using such compounds and compositions are described herein.
|
|
WO/2005/095438A1 |
The present invention relates to steroidal saponins, the preparation thereof, and the use of the same in prevention of cardio-vascular diseases of myocardial infarction or the like. The chemical formula of such steroidal saponins is the ...
|
|
WO/2005/092913A1 |
Processes are described for epoxidation reactions. In particular, the process comprises the conversion of a steroid substrate having an olefinic unsaturation in the steroid nucleus to a structure comprising a 9,11-epoxy substituent by re...
|
|
WO/2005/082392A1 |
A composition for treating or preventing diseases due to an antimutagenic effect, an antigenotoxic effect, a tumor cell-specific growth inhibitory effect, a p53 activating effect or a telomerase inhibitory which contains a leaf extract f...
|
|
WO/2005/063777A1 |
A prodrug of a corticosteroid, lidocaine or related local anesthetic composition for formulation for delivery by aerosolization to inhibit inflammation in asthmatic lungs is described. The prodrug is preferably formulated in a 5 ml solut...
|
|
WO/2005/063789A1 |
The present invention provides a process for the isolation of Bivittoside-D, a triterpenoid saponin from the sea cucumber Bohadschia vitiensis and its potent spermicidal and fungicidal activity.
|
|
WO/2005/063790A1 |
The present invention provides a novel saponin tigogenin penta glycoside isolated from the aerial parts of Chlorophytum nimonii and a process for the isolation thereof as well as its use in anti-hyperglycemic and hypolipidemic activities.
|
|
WO/2005/058935A2 |
This invention relates to a method for the preparation of sterile aqueous suspensions of ciclesonide by sterilization with moist heat. The invention further relates to pharmaceutical compositions in particular to sterile aqueous suspensi...
|
|
WO/2005/028495A1 |
A compound of formula (I) wherein R1 and R2 are the same or different and each represents hydrogen, halogen or a methyl group; R3 represents H, Cl, F, OH OR OC(O)R6; R4 represents hydrogen or methyl, R5 represents -(CH2)n-CH=CH)m-Cycl or...
|
|
WO/2005/007668A1 |
A production process for 16-dehydropregnenoneol and its analogs is provided. In which, the psudosapogenin decomposed from steroid sapogenin, with or without purification, reacts with hydrogen peroxide in the organic solvent under the pre...
|
|
WO/2005/005454A1 |
The present invention relates to steroid modified chacotrioses and the synthesis thereof as well as to intermediate compounds useful for the synthesis of the steroid modified chacotrioses and solatrioses. Moreover, the present invention ...
|
|
WO/2005/000869A1 |
Novel pentacyclic steroids and pentacyclic D-homosteroids comprising: (i) the tetracyclic steroid ring system or tetracyclic D-homosteroid ring system, respectively; (ii) a C(3) substituent selected from the group consisting of (a) a hyd...
|
|
WO/2004/085457A2 |
There is provided a compound of Formula (I) wherein (I) R1 is a selected from (i) an alkyloxyalkyl group (ii) a nitrile group, and wherein R2 is capable of forming a hydrogen bond (iii) alkylaryl group, wherein the aryl group is substitu...
|
|
WO/2004/085460A1 |
The invention relates to a novel process for preparing crystalline ciclesonide with an advantageous particle size and to the use for producing pharmaceutical preparations, in particular for topical use. The crystalline ciclesonide obtain...
|
|
WO/2004/082631A2 |
A method of inhibiting the hyperproliferation of malignant or neoplastic cells, comprising treating the cells with an antiproliferative amount of l&agr ,24(S)-dihydroxyvitamin D2. The method also includes the co-administration of cyotoxi...
|
|
WO/2004/060906A1 |
The present invention provides an improved process for the preparation of Guggulsterones which comprises epoxidising 16-dihydropegnenolone acetate (16 DPA) by reacting 16DPA with hydrogen peroxide reagent adduct in the presence of a co-b...
|
|
WO/2004/052911A1 |
An improved stereoselective process for the preparation of 6&agr -fluoropregnane derivatives of formula (I), comprising the reaction of 3-benzoyloxy-&Dgr 3,5-pregnane derivatives of formula (II), with an electrophilic fluorination agent ...
|
|
WO/2004/052912A1 |
Process for the preparation of polyhalogenated steroids, in particular of androstanic fluoro derivatives corticosteroids by means of the formation of new androstanic S-hydroxy alkyl or aralkyl-17-carbothioate intermediates.
|
|
WO2002101014B1 |
A novel process for making estra-4,9(10)-diene-3,17-dione steroids from readily available 19-nor-androst-4-ene-3-one steroids by a straightforward three-step process. Products of this process are important intermediates in the preparatio...
|
|
WO/2004/037845A1 |
A method to stereospecifically prepare a steroidal sapogenin or a derivative thereof by reducing a 3-keto,5β-H steroidal sapogenin with a hindered organoborane or an organo-aluminium hydride. A 3β-hydroxy,5β-H steroidal sapogenin or d...
|
|
WO/2004/033478A2 |
A genus of 11,21-dihydroxypregna-1,4-diene-3,20-diones is disclosed, in which the 21-hydroxy is esterified with C8 to C24 hydrocarbon or the residue of misoprostol. The compounds are useful for treating rhinitis and asthma, particularly ...
|
|
WO2003070745B1 |
Carbonates and carbamates of the formula and related steroid carbonates and carbamates are disclosed. The compounds are useful for treating rhinitis and asthma, particularly by inhalation, and for treating inflammation, particularly by l...
|
|
WO/2004/005314A1 |
The present invention is directed to novel estrieno[3,2-b]/[3,4-c]pyrrole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and diseases mediated by an estrogen receptor.
|
|
WO/2004/002504A1 |
The invention relates to a method for preparing an saponin-containing aqueous extract on the basis of a waste product from a butter tree of the Sapotaceae family, said method comprising the following steps: (i) mixing one part waste prod...
|
|
WO/2003/092578A2 |
The present invention relates to improved methods for synthesising cyproterone acetate (17&agr -Acetoxy-6-chloro-1&agr , 2&agr -methylene-4,6-pregnadiene-3,20-dione) from solasodine. The methods of the invention are shorter as those of t...
|
|
WO/2003/082893A2 |
The invention discloses therapeutic methods and uses of certain steroidal sapogenins, related compounds and derivatives thereof, in the treatment of non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, motor-sensory...
|
|
WO/2003/082896A2 |
The process for the preparation of 6&agr -fluoro steroids, comprising the reaction of the corresponding 6β-fluoro steroids, or of 6&agr /6β isomeric mixtures with an organic base having a diazo iminic group, in a suitably selected orga...
|
|
WO/2003/082894A2 |
Novel processes for the C-17 spirolactonization and 6,7 oxidation of steroid compounds are provided. In certain preferred embodiments, the present invention provides for the preparation of steroid compounds which are useful in the prepar...
|
